Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Alnylam Pharmace. buy UBS Group AG

Alnylam Pharmace.
Start price
€228.00
28.06.24 / 50%
Target price
€268.93
28.06.25
Performance (%)
1.62%
Price
€231.70
05.07.24
Summary
This prediction is currently active. The BUY prediction by UBS_Group_AG shows slight gains of 1.62%. This prediction currently runs until 28.06.25. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Performance without dividends (%)
Name 1w
Alnylam Pharmace. 2.115%
iShares Core DAX® 1.395%
iShares Nasdaq 100 2.287%
iShares Nikkei 225® 1.617%
iShares S&P 500 0.659%

Comments by UBS_Group_AG for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Buy
Perf. (%) 1.62%
Target price 268.934
Change
Ends at 28.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $253.00 to $288.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat

UBS Group AG 
0
Report Share
28.06.24